Rapport Therapeutics (NASDAQ:RAPP) Director Paul Silva Buys 3,680 Shares of Company Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Paul Silva bought 3,680 shares of the company’s stock in a transaction that occurred on Thursday, October 22nd. The stock was purchased at an average price of $27.07 per share, with a total value of $99,617.60. Following the transaction, the director directly owned 3,680 shares in the company, valued at $99,617.60. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Rapport Therapeutics Stock Up 5.9%

Shares of RAPP opened at $26.53 on Friday. The stock has a 50 day simple moving average of $39.44 and a two-hundred day simple moving average of $39.02. Rapport Therapeutics, Inc. has a 1 year low of $23.75 and a 1 year high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, equities research analysts forecast that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Key Stories Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The candidate produced statistically significant placebo-adjusted improvements in YMRS and CGI-BP mania-severity scores. Rapport plans to begin Phase 3 trials, potentially expanding RAP-219’s commercial opportunity beyond epilepsy. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts increased or maintained bullish valuations. JonesTrading raised its target to $82, while BTIG reportedly lifted its target to $89. Raymond James raised its target to $86, and HC Wainwright reaffirmed its Buy rating. The consensus target is approximately $68.36, well above recent trading levels. BTIG price target increase
• Positive Sentiment: Company insiders made substantial open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while four directors purchased an additional 52,594 shares. The combined purchases were worth approximately $1.57 million and may signal management confidence following the clinical update. SEC insider filings
• Neutral Sentiment: RAP-219’s move toward Phase 3 is an important milestone, but investors still face clinical, regulatory, financing, and commercialization uncertainty typical of a clinical-stage biotechnology company.
• Negative Sentiment: The clinical results may have been less decisive than some investors expected. Reports indicated that portions of the data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport also remains unprofitable; its latest quarterly loss exceeded analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. Rapport bipolar data report

Hedge Funds Weigh In On Rapport Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV purchased a new position in Rapport Therapeutics in the 1st quarter worth approximately $30,000. Sterling Capital Management LLC boosted its stake in shares of Rapport Therapeutics by 597.9% during the third quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after purchasing an additional 843 shares during the period. State of Wyoming purchased a new stake in shares of Rapport Therapeutics during the second quarter valued at approximately $65,000. Meeder Asset Management Inc. bought a new position in shares of Rapport Therapeutics in the second quarter worth approximately $116,000. Finally, AlphaCentric Advisors LLC grew its holdings in shares of Rapport Therapeutics by 6.8% in the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after purchasing an additional 408 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on RAPP. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 price objective on shares of Rapport Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, October 15th. Wall Street Zen downgraded shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. UBS Group began coverage on shares of Rapport Therapeutics in a research note on Thursday, October 15th. They issued a “buy” rating and a $71.00 price target for the company. Finally, Wells Fargo & Company cut their price target on shares of Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating for the company in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $68.36.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.